Market closed
Natera/$NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
4,429
ISIN
US6323071042
Website
Natera Metrics
BasicAdvanced
$21B
-
-$1.48
1.79
-
Price and volume
Market cap
$21B
Beta
1.79
52-week high
$183.00
52-week low
$92.14
Average daily volume
1.5M
Financial strength
Current ratio
3.873
Quick ratio
3.582
Long term debt to equity
8.313
Total debt to equity
14.794
Interest coverage (TTM)
-26.52%
Management effectiveness
Return on assets (TTM)
-8.87%
Return on equity (TTM)
-18.66%
Valuation
Price to revenue (TTM)
11.013
Price to book
17.25
Price to tangible book (TTM)
17.25
Growth
Revenue change (TTM)
51.50%
Earnings per share change (TTM)
-52.41%
3-year revenue growth (CAGR)
40.00%
3-year earnings per share growth (CAGR)
-36.85%
What the Analysts think about Natera
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Natera Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Natera Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Natera News
AllArticlesVideos
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
Business Wire·1 week ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Seeking Alpha·2 weeks ago
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $21B as of May 14, 2025.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of May 14, 2025.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.